SPX4,249.33
0.93%Positive
IXIC12,989.17
1.05%Positive
DJI33,579.21
0.81%Positive
STOXX440.53
0.15%Positive
FTSE7,466.66
0.54%Negative
N22527,819.33
0.65%Negative

Innoviva Inc

INVA.O

Official Data Partner

Latest Trade: trading higher14.5USD
Change: 0
% Change: 0.00%

As of Aug 11 2022. Values delayed up to 15 minutes

Day Range: -- - --
52-Week Range: 13.64 - 20.71

Previous Close: 14.50
Open: 0.00
Volume: 0.00
3 Month Average Trading Volume: 17.83
Shares Out (Mil): 69.71
Market Cap: 1,010.74
Forward P/E: 11.89
Dividend Yield: -99,999.99

Key Statistics

3 mean rating - 3 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): 11.27
Price To Sales (TTM): 2.50
Price To Book (Quarterly): 2.60
Price To Cash Flow (Per Share TTM): 4.56
Total Debt/Total Equity (Quarterly): 138.86
Long Term Debt/Equity (Quarterly): 114.12
Return On Investment (TTM): 26.70
Return On Equity (TTM): 21.54

2021 (millions USD)

About Innoviva Inc (INVA.O)

Company Information

Innoviva, Inc. is a holding company. The Company owns a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited, including RELVAR/BREOELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) collaboration agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). Its TRELEGY ELLIPTA is a once-daily combination medicine consisting of an ICS, long-acting muscarinic antagonist (LAMA) and LABA. Its portfolio also includes sulbactam-durlobactam (SUL-DUR), which is into treatment of multidrug-resistant Gram-negative bacteria.